Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors
Authors
Choi, J.Anderson, R.
Blidner, A.
Cooksley, Timothy J
Dougan, M.
Glezerman, I.
Ginex, P.
Girotra, M.
Gupta, D.
Johnson, D.
Shannon, V. R.
Suarez-Almazor, M.
Rapoport, B. L.
Lacouture, M. E.
Affiliation
Division of Oncodermatology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.Issue Date
2020
Metadata
Show full item recordAbstract
Immune checkpoint inhibitors (ICIs) frequently result in cutaneous immune-related adverse events (IrAEs). Although the majority of these events are mild-to-moderate in severity, up to 5% are severe, which may lead to morbidity and dose interruption or discontinuation of ICI therapy. In addition, up to 25% of dermatologic IrAEs are corticosteroid-refractory or corticosteroid-dependent. These 2020 MASCC recommendations cover the diagnosis and management of cutaneous IrAEs with a focus on moderate-to-severe and corticosteroid-resistant events. Although the usage of immune-suppressive therapy has been advocated in this setting, there is a lack of randomized clinical trial data to provide a compelling level of evidence of its therapeutic benefit.Citation
Choi J, Anderson R, Blidner A, Cooksley T, Dougan M, Glezerman I, et al. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors. Supportive Care in Cancer. 2020.Journal
Supportive Care in CancerDOI
10.1007/s00520-020-05706-4PubMed ID
32856211Additional Links
https://dx.doi.org/10.1007/s00520-020-05706-4Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1007/s00520-020-05706-4